Last updated: March 13, 2026
What Is NDC 00603-0213?
NDC 00603-0213 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. The code corresponds to Vigamox (moxifloxacin ophthalmic solution) 0.5%. This drug is an antibiotic used to treat bacterial conjunctivitis.
Product Details:
- Manufacturer: Alcon Laboratories, Inc.
- Packaging: 10 mL bottles
- Indications: Bacterial conjunctivitis, prophylaxis of bacterial eye infections
Market Landscape
Market Size
The global ophthalmic antibiotics market was valued at approximately USD 1.2 billion in 2022 and is projected to reach USD 1.6 billion by 2028. The compound annual growth rate (CAGR) during this period is forecast at around 4.5%.
Key Competitors
- Vigamox (Alcon)
- Zymar (Allergan, now AbbVie)
- Besivance (Bausch + Lomb)
- Levofloxacin ophthalmic (various generics)
Vigamox holds an estimated market share of 35% of ophthalmic antibiotics in the United States, driven primarily by brand recognition and prescriber loyalty.
Distribution Channels
- Prescription fulfillment through ophthalmologists and general practitioners
- Supply via hospital outpatient pharmacies
- Increasing penetration in emerging markets
Regulatory Status
Vigamox was approved by the FDA in 2009. It holds a standard 5-year patent, with generic versions entering the market in 2014 after patent expiration, which impacts pricing and market share dynamics.
Price Analysis
Historical Pricing
In the US, average wholesale prices (AWP) and typical retail prices for a 10 mL bottle have historically been:
| Year |
Wholesale Price (USD) |
Estimated Retail Price (USD) |
| 2018 |
USD 85 |
USD 120 |
| 2020 |
USD 80 |
USD 115 |
| 2022 |
USD 78 |
USD 110 |
These prices are for brand-name Vigamox; generics typically retail at a 15–25% discount.
Patent Expiry and Generic Entry
Patent expiration in 2014 led to generic versions, significantly reducing prices:
- Generics price range in 2022: USD 40–60 per 10 mL bottle.
- Brand premium persists due to brand loyalty, with prices typically 50% higher than generics.
Price Dynamics & Future Projections
- The recent entry of generics has stabilized and driven down prices.
- Expected price trend over the next 3-5 years:
- Slight rebound in brand-name prices as supply contracts
- Continued price stability for generics, with minor fluctuations in the USD 40-60 range
- Projections:
- Brand-name Vigamox could stabilize around USD 80–90 given small-market recovery efforts
- Generics remain between USD 40–55
Pricing Policies Impacting Market
- Manufacturers' pricing strategies focus on maintaining market share via price discounts to prescribers and wholesalers.
- Insurance reimbursement policies influence retail pricing, with copays affecting consumer access.
- Ongoing patent disputes and legal challenges may impact future pricing if patent protections are re-established or extended.
Market Trends Influencing Future Outlook
- Increasing adoption of generic antibiotics due to cost benefits.
- Rising ophthalmic infection rates in aging populations.
- Adoption of newer antibiotic formulations with improved efficacy and reduced resistance.
- Regulatory pressures to lower drug prices, especially in government-funded healthcare systems.
Price Projections Summary
| Year |
Brand Vigamox Price (USD) |
Generic Price Range (USD) |
| 2023 |
USD 85–90 |
USD 40–55 |
| 2024 |
USD 85–90 |
USD 40–55 |
| 2025 |
USD 80–85 |
USD 40–55 |
| 2026 |
USD 80–85 |
USD 40–55 |
Key Takeaways
- Vigamox remains a significant player in ophthalmic antibiotics but faces pricing pressure from generics.
- US retail prices for brand Vigamox range from USD 110 to USD 120, while generics trade at USD 40 to USD 60.
- Price stability is anticipated over the next five years, with slight declines in the generic segment.
- Market growth will likely be driven by increasing ophthalmic infection prevalence and new formulations, despite downward pressure on prices.
- Major regulatory, patent, and policy shifts could alter pricing and market share dynamics.
FAQs
1. How does patent expiration affect Vigamox pricing?
Patent expiration led to the entry of generics, reducing prices by approximately 50% and increasing market competition.
2. What factors influence future price trends for ophthalmic antibiotics?
Market competition, generic penetration, regulatory policies, and infection prevalence directly impact prices.
3. Are there any upcoming regulatory changes expected to influence pricing?
Potential patent litigations or policies aimed at drug price control could affect prices, but no significant reform is projected in the near term.
4. How do insurance reimbursements impact consumer prices?
Reimbursement levels set by insurers influence copayment amounts, which affect retail prices and patient access.
5. What is the outlook for revenue growth in this segment?
Revenue growth remains steady in the US, driven by infection rates and new formulations, but overall market prices are under pressure from generics.
References
- MarketsandMarkets. (2023). Ophthalmic antibiotics market forecast. Available at: [Link]
- U.S. Food and Drug Administration. (2009). FDA approval for Vigamox. Available at: [Link]
- IQVIA. (2022). Pharmaceutical pricing and market share analysis. Available at: [Link]
- Retail pharmacy pricing data. (2022). Price analyses of ophthalmic antibiotics. Available at: [Link]
- Patent status and legal updates. (2022). Vigamox patent and generic market entry. Available at: [Link]
